UnitedHealth Continues Its Acquisition Spree

This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus.

From the editor-in-chief of Evidence-Based Oncology™.

Rebecca Kaul, MBA, vice president and chief innovation officer at The University of Texas MD Anderson Cancer Center, said the best technology improves the patient experience.

Diabetic retinopathy costs the United States $6.2 billion a year. Better screening techniques that can catch neurodegeneration at earlier stages have the potential to cut costs and improve quality of life for patients.

Patients to benefit from new technology that enables physicians to more accurately diagnose and locate cancers.

Adding measurement of a key protein during metabolic assessment could help identify those at higher risk of heart attacks and strokes even if they have normal body mass index.